<?xml version="1.0" encoding="UTF-8"?>
<ref id="B116-molecules-25-04036">
 <label>116.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Dâ€™Souza</surname>
    <given-names>D.C.</given-names>
   </name>
   <name>
    <surname>Perry</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>MacDougall</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Ammerman</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Cooper</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Wu</surname>
    <given-names>Y.-T.</given-names>
   </name>
   <name>
    <surname>Braley</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Gueorguieva</surname>
    <given-names>R.V.</given-names>
   </name>
   <name>
    <surname>Krystal</surname>
    <given-names>J.H.</given-names>
   </name>
  </person-group>
  <article-title>The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis</article-title>
  <source>Neuropsychopharmacology</source>
  <year>2004</year>
  <volume>29</volume>
  <fpage>1558</fpage>
  <lpage>1572</lpage>
  <pub-id pub-id-type="doi">10.1038/sj.npp.1300496</pub-id>
  <?supplied-pmid 15173844?>
  <pub-id pub-id-type="pmid">15173844</pub-id>
 </element-citation>
</ref>
